This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Gloria Lena Vega, PhD; Scott M. Grundy, MD, PhD

Arch Intern Med. 1990;150(6):1313-1319.

Abstract
• Many patients with high levels of serum total cholesterol have a concomitant elevation of serum triglyceride levels and thus have mixed hyperlipidemia. In this study, 13 patients with mixed hyperlipidemia were treated with the cholesterol-lowering drug lovastatin to determine its effectiveness. In 9 of these patients, lovastatin therapy used alone was compared with the drug combination of lovastatin and gemfibrozil. In the 13 patients, lovastatin therapy produced a 31% reduction in total cholesterol level and a 32% decrease in triglyceride levels compared with placebo. It lowered very-low-density plus intermediate-density lipoprotein cholesterol levels by 40%, low-density lipoprotein cholesterol levels by 36%, and total apolipoprotein B levels by 28%. Concentrations of high-density lipoprotein cholesterol and apolipoprotein A-I were unchanged, but total cholesterol (and low-density lipoprotein cholesterol)/high-density lipoprotein cholesterol ratios were markedly reduced. Compared with lovastatin alone, lovastatin plus gemfibrozil produced greater decreases in very-low-density plus intermediate-density lipoprotein cholesterol levels and an increase in high-density lipoprotein cholesterol levels, but, in view of the higher risk for severe myopathy with this combination, lovastatin used alone may be adequate therapy for many patients with mixed hyperlipidemia.

(Arch Intern Med. 1990;150:1313-1319)

Author Affiliations
From the Center for Human Nutrition (Drs Vega and Grundy), Departments of Clinical Nutrition (Drs Vega and Grundy), Internal Medicine (Dr Grundy), and Biochemistry (Dr Grundy), University of Texas Southwestern Medical Center at Dallas, and Veterans Administration Medical Center (Dr Grundy), Dallas.

Footnotes
Accepted for publication October 31,1989.

Reprint requests to Center for Human Nutrition, Department of Clinical Nutrition, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75235 (Dr Vega).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Non-High-Density Lipoprotein Cholesterol Level as Potential Risk Predictor and Therapy Target
Grundy
Arch Intern Med 2001;161:1379-1380.
FULL TEXT  

Comparative Efficacy and Safety of Micronized Fenofibrate and Simvastatin in Patients With Primary Type Ha or IIb Hyperlipidemia
Farnier et al.
Arch Intern Med 1994;154:441-449.
ABSTRACT  

Comparison of Gemfibrozil and Lovastatin in Patients With High Low-Density Lipoprotein and Low High-Density Lipoprotein Cholesterol Levels
McKenney et al.
Arch Intern Med 1992;152:1781-1787.
ABSTRACT  

Two Different Views of the Relationship of Hypertriglyceridemia to Coronary Heart Disease: Implications for Treatment
Grundy and Vega
Arch Intern Med 1992;152:28-34.
ABSTRACT  

Myopathy and Rhabdomyolysis With Lovastatin Taken With Gemfibrozil
Goldstein
JAMA 1990;264:2991-2991.
ABSTRACT  

Primary Hypertriglyceridemia With Borderline High Cholesterol and Elevated Apolipoprotein B Concentrations: Comparison of Gemfibrozil vs Lovastatin Therapy
Vega and Grundy
JAMA 1990;264:2759-2763.
ABSTRACT  

Role of Apolipoprotein Levels in Clinical Practice
Grundy and Vega
Arch Intern Med 1990;150:1579-1582.
ABSTRACT